Loading...
3 results
Search Results
Now showing 1 - 3 of 3
- Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η5-C5H5)(PPh3)2]+ as Promising Drugs Against Cisplatin-Resistant Cancer Cells and Human Mesenchymal Stem CellsPublication . Gouveia, Marisol; Figueira, João; Jardim, Manuel G.; Castro, Rita; Tomás, Helena; Rissanen, Kari; Rodrigues, JoãoHere and for the first time, we show that the organometallic compound [Ru(η5-C5H5)(PPh3)2Cl] (RuCp) has potential to be used as a metallodrug in anticancer therapy, and further present a new approach for the cellular delivery of the [Ru(η5-C5H5)(PPh3)2]+ fragment via coordination on the periphery of low-generation poly(alkylidenimine) dendrimers through nitrile terminal groups. Importantly, both the RuCp and the dendrimers functionalized with [Ru(η5-C5H5)(PPh3)2]+ fragments present remarkable toxicity towards a wide set of cancer cells (Caco-2, MCF-7, CAL-72, and A2780 cells), including cisplatin-resistant human ovarian carcinoma celllines(A2780cisRcells). Also,RuCpandthepreparedmetallodendrimersareactiveagainsthuman mesenchymal stem cells (hMSCs), which are often found in the tumor microenvironment where they seem to play a role in tumor progression and drug resistance.
- Metalodendrímeros de baixa geração utilizando dendrímeros poli(alquilideno imina) funionalizados com nitrilos: estudos de citotoxicidadePublication . Gouveia, Marisol Fátima Sánchez de; Rodrigues, João Manuel Cunha; Tomás, Helena Maria Pires Gaspar
- Poly(alkylidenamines) dendrimers as scaffolds for the preparation of low-generation ruthenium based metallodendrimersPublication . Rodrigues, João; Jardim, Manuel G.; Figueira, João; Gouveia, Marisol; Tomás, Helena; Rissanen, KariThe aim of this article is to highlight the use of nitrile-functionalized poly(alkylidenamines) dendrimers as building blocks for the preparation of low-generation ruthenium based cationic metallodendrimers having in view potential biomedical applications. Air-stable poly(alkylidenamines) nitrile dendrimers, peripherally functionalized with the ruthenium moieties [Ru(Z5-C5H5)(PPh3)2]+ or [RuCl(dppe)2]+, have been prepared, characterized and are being studied for their anticancer activity. The followed strategy is based on the biological advantages associated with low-generation dendrimers, the known activity of ruthenium compounds as anticancer drugs and the stability of these dendrimers at the physiological temperature.